WCN26-3663 BAXHTN – EFFICACY AND SAFETY OF THE ALDOSTERONE SYNTHASE INHIBITOR BAXDROSTAT IN PATIENTS WITH UNCONTROLLED OR RESISTANT HYPERTENSION

Read full text Summarise with VIRAT
Authors: Hirotaka Shibata, Michel Azizi, Jenifer Michelle Brown, Jamie P. Dwyer, John M. Flack, Jakub Fronczek, Erika Jones, Daniel S Olsson, Shira Perl, Ji-Guang Wang, Ulrica Wilderäng, Janet Turk Wittes
+1 more Bryan Williams
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BaxHTN (NCT06034743) is an international, randomised, double-blind, placebo-controlled trial evaluating the efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).

Fields of Study & Subjects

Hormonal Regulation and Hypertension Blood Pressure and Hypertension Studies Renin-Angiotensin System Studies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105030–105030
Publication date
25 March 2026
Language
EN